Cantor Fitzgerald Weighs in on BCYC FY2026 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Bicycle Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($4.03) per share for the year. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share.

Several other research analysts have also weighed in on the stock. Royal Bank of Canada reduced their price objective on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley set a $17.00 price target on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a research note on Monday, May 5th. B. Riley cut their price target on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Finally, JMP Securities lowered their target price on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Bicycle Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $25.00.

Bicycle Therapeutics Price Performance

Shares of BCYC stock traded up $0.10 during trading hours on Tuesday, reaching $8.64. The company had a trading volume of 112,855 shares, compared to its average volume of 390,375. Bicycle Therapeutics has a 1-year low of $6.10 and a 1-year high of $28.67. The firm has a market cap of $598.35 million, a price-to-earnings ratio of -2.63 and a beta of 1.46. The company has a 50 day moving average of $7.97 and a 200 day moving average of $11.53.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $9.98 million for the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BCYC. Point72 Asset Management L.P. boosted its stake in Bicycle Therapeutics by 406.2% in the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company's stock valued at $63,769,000 after purchasing an additional 3,655,101 shares during the period. Baker BROS. Advisors LP lifted its holdings in shares of Bicycle Therapeutics by 15.8% during the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after buying an additional 1,485,397 shares in the last quarter. Fcpm Iii Services B.V. lifted its holdings in shares of Bicycle Therapeutics by 47.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after buying an additional 1,112,369 shares in the last quarter. Long Focus Capital Management LLC boosted its position in shares of Bicycle Therapeutics by 138.2% in the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company's stock valued at $10,984,000 after acquiring an additional 750,661 shares during the period. Finally, Armistice Capital LLC boosted its position in shares of Bicycle Therapeutics by 21.7% in the first quarter. Armistice Capital LLC now owns 2,672,000 shares of the company's stock valued at $22,685,000 after acquiring an additional 476,000 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.